About Vaxxinity
Vaxxinity is a company based in Dallas (United States) founded in 2019. Vaxxinity has raised $26.96 million across 1 funding round. Vaxxinity operates in a competitive market with competitors including Brii Biosciences, Affinivax, Osivax, Diamyd Medical and Pardes Biosciences, among others.
- Headquarter Dallas, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vaxxinity, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$56.93 M (USD)24.31as on Dec 31, 2023
-
EBITDA
-$56.05 M (USD)24.56as on Dec 31, 2023
-
Total Equity Funding
$26.96 M (USD)
in 1 rounds
-
Latest Funding Round
$26.96 M (USD), Series B
Mar 31, 2021
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vaxxinity
Vaxxinity is a publicly listed company on the OTC with ticker symbol VAXX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Vaxxinity
Unlock access to complete
Unlock access to complete
Funding Insights of Vaxxinity
Vaxxinity has successfully raised a total of $26.96M through 1 strategic funding round. The most recent funding activity was a Series B round of $26.96 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Vaxxinity
Investment portfolio details for Vaxxinity
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vaxxinity
Detailed financials for Vaxxinity
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vaxxinity Comparisons
Peer comparison for Vaxxinity
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vaxxinity
Vaxxinity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, Affinivax, Osivax, Diamyd Medical and Pardes Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines against mutating pathogens are developed using nanoparticle technology.
|
|
| Locked | Locked | Locked |
Therapies for autoimmune diabetes treatment and prevention are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| Locked | Locked | Locked |
Developing and licensing novel drugs for diseases including cancer and autoimmune diseases
|
Detailed competitors of Vaxxinity
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vaxxinity
Complete news archive for Vaxxinity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vaxxinity
Vaxxinity was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Vaxxinity is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Vaxxinity is a funded company, having raised a total of $26.96M across 1 funding round to date.
Vaxxinity was established in 2019 in Dallas, United States, within the biotechnology sector. Focus is placed on developing vaccines addressing neurological disorders and infectious diseases through proprietary synthetic peptide immunogens. These immunogens activate B- and T-cell responses while combining multiple antigens into multitope formulations. Key candidates include UB-612 for COVID-19, UB-311 and Tau for Alzheimers disease, UB-312 for Parkinsons disease, UB-313 for chronic migraine, and PCSK9 for hypercholesterolemia.
Vaxxinity's top competitors include Brii Biosciences, Osivax and CStone Pharma.
Yes, Vaxxinity is publicly traded on OTC under the ticker symbol VAXX.
The ticker symbol of Vaxxinity is VAXX on OTC.